EUTOS score is able to predict optimal response to imatinib, in particular, achievement of molecular response at 3 months, a marker of emerging importance in predicting long-term outcome, and of CCyR at 6 months, that has been associated with superior progression-free and overall survival. Sokal score predict sensibly cytogenetic responses, but seems less efficacious in identifying patients that will achieve optimal molecular endpoints.

EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations

BONIFACIO, Massimiliano;
2013-01-01

Abstract

EUTOS score is able to predict optimal response to imatinib, in particular, achievement of molecular response at 3 months, a marker of emerging importance in predicting long-term outcome, and of CCyR at 6 months, that has been associated with superior progression-free and overall survival. Sokal score predict sensibly cytogenetic responses, but seems less efficacious in identifying patients that will achieve optimal molecular endpoints.
2013
chronic myeloid leukemia; EUTOS score; Sokal score; imatinib
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/893390
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 7
social impact